Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study

Parit, Rahul; Jayavel, S R I D H A R

doi:10.1016/j.ejphar.2021.173899

Cited by 37 publications

(54 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One recent study [26] found that the mRNA level of ACE2 was increased in the proximal tubular epithelial cells of DKD patients. In addition, some studies [27,28] have shown that RAAS inhibitors upregulate the expression of ACE2. ACE2 is the receptor for SARS-CoV-2 [29][30][31], which is responsible for the COVID-19 outbreak, giving rise to the following two questions: will renal injury be increased in COVID-19 patients with diabetes and will ACEi/ARB treatment have an impact on the renal outcome of COVID-19 patients with diabetes?…”

Section: Discussionmentioning

confidence: 99%

The evolution and future of diabetic kidney disease research: a bibliometric analysis

Wei

Jiang

2021

BMC Nephrol

View full text Add to dashboard Cite

Background Diabetic kidney disease (DKD) is one of the most important complications of diabetic mellitus. It is essential for nephrologists to understand the evolution and development trends of DKD. Methods Based on the total cited numbers in the Web of Science Core Collection, which was searched through September 28th, 2020, we performed a bibliometric analysis of the top 100 most cited full-length original articles on the subject of DKD. The timespans, authors, contributions, subcategories, and topics of those 100 articles were analysed. In addition, the evolution of topics in DKD research was investigated. Results There were 23,968 items under the subject of DKD in the Web of Science Core Collection. The top 100 cited articles, published from 1999 to 2017, were cited 38,855 times in total. Researchers from the USA contributed the most publications. The number of articles included in ‘Experimental studies (EG)’, ‘Clinical studies (CS)’, ‘Epidemiological studies (ES)’, and ‘Pathological and pathophysiological studies (PP)’ were 65, 26, 7, and 2, respectively. Among the 15 topics, the most popular topic is the renin-angiotensin-aldosterone system (RAAS), occurring in 26 articles, including 6 of the top 10 most cited articles. The evolution of topics reveals that the role of RAAS inhibitor is a continuous hotspot, and sodium-glucose cotransporter 2 (SGLT-2) inhibitor and glucagon-like peptide 1 (GLP-1) agonist are two renoprotective agents which represent novel therapeutic methods in DKD. In addition, the 26 clinical studies among the top 100 most cited articles were highlighted, as they help guide clinical practice to better serve patients. Conclusions This bibliometric analysis of the top 100 most cited articles revealed important studies, popular topics, and trends in DKD research to assist researchers in further understanding the subject.

show abstract

Section: Discussionmentioning

confidence: 99%

The evolution and future of diabetic kidney disease research: a bibliometric analysis

Wei

Jiang

2021

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…Other studies [43,44] also supported the nondiscontinuation of these drugs during hospitaziolation from Covid-19. Among them, in fact, a large fraction is being administered either ACE inhibitors or Angiotensin II blockers, due to epidemiological data showing cardiopathies, diabetes mellitus and hypertension to be the most frequent comorbidities found among those patients [45].…”

Section: The Role Of Ace2 In Covid-19 Pathogenesismentioning

confidence: 99%

Arterial and Venous Thrombosis in COVID-19 Disease: From Molecular Pathway to Vaccine Administration

Nappi¹,

Iervolino²,

Singh³

2021

Preprint

View full text Add to dashboard Cite

The Coronavirus 2 (SARS-CoV-2) infection is a global pandemic that has affected millions of people worldwide. The advent of vaccines, however, has permitted some restitution. Aside from the respiratory complications of the infection, there is also a thrombotic risk attributed to both the disease alongside the vaccine. There are no reliable data for the risk of thromboembolism in SARS-CoV-2 infection in patients managed out with the hospital setting. A literature review was performed to identify the pathophysiological mechanism of thrombosis from the SARS-CoV-2 infection including the role of Angiotensin-Converting Enzyme receptors. The impact of the vaccine and likely mechanisms from thrombosis following vaccination was also clarified. Finally, the utility of the vaccines available against the multiple variants is also highlighted. The systemic response to SARS-CoV-2 infection is still relatively poorly understood, but several risk factors have been identified. The roll-out of the vaccines worldwide has also allowed the lifting of lockdown measures and a reduction in the spread of the disease. The experience of the SARS-CoV-2 infection, however, has highlighted the crucial role of epidemiological research and the need for ongoing studies within this field.

show abstract

“…(1) The first is blocking the endocytosis of SARS-CoV-2. It has been reported that SARS-CoV-2 can bind to ACE-2, by which it can infect the host cells [14,15]. However, the actual blocking mechanism of NIC on the ACE-2 protein is still not clear [16].…”

Section: Introductionmentioning

confidence: 99%

Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment

Piao

Rejinold

et al. 2021

Polymers

View full text Add to dashboard Cite

Niclosamide (NIC), a conventional anthelmintic agent, is emerging as a repurposed drug for COVID-19 treatment. However, the clinical efficacy is very limited due to its low oral bioavailability resulting from its poor aqueous solubility. In the present study, a new hybrid drug delivery system made of NIC, montmorillonite (MMT), and Tween 60 is proposed to overcome this obstacle. At first, NIC molecules were immobilized into the interlayer space of cationic clay, MMT, to form NIC–MMT hybrids, which could enhance the solubility of NIC, and then the polymer surfactant, Tween 60, was further coated on the external surface of NIC–MMT to improve the release rate and the solubility of NIC and eventually the bioavailability under gastrointestinal condition when orally administered. Finally, we have performed an in vivo pharmacokinetic study to compare the oral bioavailability of NIC for the Tween 60-coated NIC–MMT hybrid with Yomesan®, which is a commercially available NIC. Exceptionally, the Tween 60-coated NIC–MMT hybrid showed higher systemic exposure of NIC than Yomesan®. Therefore, the present NIC–MMT–Tween 60 hybrid can be a potent NIC drug formulation with enhanced solubility and bioavailability in vivo for treating Covid-19.

show abstract

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study

Cited by 37 publications

References 98 publications

The evolution and future of diabetic kidney disease research: a bibliometric analysis

The evolution and future of diabetic kidney disease research: a bibliometric analysis

Arterial and Venous Thrombosis in COVID-19 Disease: From Molecular Pathway to Vaccine Administration

Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment

Contact Info

Product

Resources

About